论文部分内容阅读
目的探讨索拉菲尼对中晚期肝癌患者的临床疗效。方法选取2014年1月至2015年7月间收治的84例中晚期肝癌患者,随机数表法分为观察组和对照组,每组42例。对照组42例患者采用经导管肝动脉化疗栓塞术(TACE)治疗,观察组42例患者在对照组治疗基础上口服索拉菲尼治疗,比较两组患者治疗的有效性和安全性。结果治疗后,观察组患者总有效率为83.3%,对照组患者为57.1%,差异有统计学意义(P<0.05)。观察组患者血清AFP和Child-Pugh评分均较对照组患者明显改善,差异有统计学意义(P<0.05)。两组患者不良反应症状均较轻,且均经对症处理好转。结论索拉菲尼治疗中晚期肝癌有利于提高患者的生活质量,不会明显增加治疗中不良反应,其疗效显著,且安全可靠,值得临床应用。
Objective To investigate the clinical efficacy of sorafenib on patients with advanced liver cancer. Methods Eighty-four patients with advanced hepatocellular carcinoma who were admitted between January 2014 and July 2015 were randomly divided into observation group and control group with 42 cases in each group. Forty-two patients in the control group were treated with transcatheter arterial chemoembolization (TACE). 42 patients in the observation group were treated with sorafenib on the basis of the control group, and the efficacy and safety of the two groups were compared. Results After treatment, the total effective rate was 83.3% in the observation group and 57.1% in the control group, the difference was statistically significant (P <0.05). The serum AFP and Child-Pugh scores of the observation group were significantly improved compared with the control group, the difference was statistically significant (P <0.05). Two groups of patients with adverse reactions were mild symptoms, and were symptomatic treatment improved. Conclusion Sorafenib treatment of advanced liver cancer is conducive to improving the quality of life of patients, does not significantly increase the adverse reactions during treatment, and its efficacy is significant, and safe and reliable, it is worth clinical application.